Key result
Dexmedetomidine-remifentanil provides deeper sedation, lower pain scores, and ~93% fewer desaturation events than midazolam-remifentanil.
Why the study?
Does dexmedetomidine-remifentanil improve sedation and analgesia compared with midazolam-remifentanil in patients undergoing catheter ablation of atrial fibrillation?
RCT (n=90)
randomized
Does dexmedetomidine-remifentanil improve sedation and analgesia compared with midazolam-remifentanil in patients undergoing catheter ablation of atrial fibrillation?
Dexmedetomidine combined with low-dose remifentanil provides superior sedation, better analgesia, and less respiratory depression than midazolam with remifentanil during atrial fibrillation ablation.
Answers are grounded in this paper and cite their sources.
Supports dexmedetomidine-remifentanil for AF ablation sedation; confirms RCT superiority over midazolam-remifentanil.
AIMS: Anaesthesia is required for catheter ablation of atrial fibrillation (A-fib) to achieve patient comfort and immobilization to avoid map shifts. This study compared the analgesic and sedative efficacies of dexmedetomidine-remifentanil with those of midazolam-remifentanil for catheter ablation of A-fib. METHODS AND RESULTS: Ninety patients were randomized to receive either intermittent midazolam boluses (1-2 mg) with 3.6-7.2 µg/kg/h of remifentanil (MR group) or dexmedetomidine 0.2-0.7 µg/kg/h after a loading dose of 1 µg/kg with 1.2-2.4 µg/kg/h of remifentanil (DR group). The sedation level assessed by the Ramsay sedation and bispectral index scores, haemodynamic variables, pain score (10-point numerical scale), and satisfaction levels of the patients and cardiologists (5-point numerical scale) were recorded. The Ramsay sedation score was significantly higher, and the bispectral index score was lower in the DR group (P< 0.001) compared with the MR group starting 10 min after drug administration. The incidence of desaturation (SpO2 < 90%) was significantly greater in the MR group compared with the DR group (15 vs. 1, P < 0.001). The pain score was significantly lower (1.72 ± 1.65 vs. 0.95 ± 1.10, P = 0.021), and the satisfaction levels of interventionists were significantly higher (2.50 ± 0.71 vs. 3.00 ± 0.63, P = 0.001) in the DR group compared with the MR group. CONCLUSION: The combination of dexmedetomidine and remifentanil provided deeper sedation, less respiratory depression, better analgesia, and higher satisfaction for the interventionist during catheter ablation of A-fib compared with midazolam plus remifentanil, even at a lower dose of remifentanil.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2013) conducted an RCT in Atrial fibrillation (n=90). Dexmedetomidine-remifentanil vs. Midazolam-remifentanil (midazolam 1-2 mg boluses with remifentanil 3.6-7.2 µg/kg/h) was evaluated on Sedation level assessed by Ramsay sedation and bispectral index scores (p=<0.001). Dexmedetomidine-remifentanil provided deeper sedation, fewer desaturation events, and lower pain scores compared with midazolam-remifentanil.
Synapse has enriched 10 related papers. Consider them for comparative context: